(thirdQuint)The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

.

 All subjects will receive a myeloablative or reduced intensity conditioning regimen, after which they will receive 2 HLA-matched UCB units.

 A total of 40 subjects will receive one ProHema-CB as part of a double CB transplant and an additional 20 subjects will be enrolled as concurrent controls.

 The determination of which CB unit will be the ProHema-CB unit will be made based primarily upon the degree of HLA match.

.

 The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

@highlight

This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies.

 A maximum of 60 eligible subjects will be enrolled and treated in the trial at approximately 10 centers within the U.

S.

